INTRODUCTION
A wide range of viruses can affect the respiratory tract; in general, these can be divided into viruses for which the primary site of infection is the respiratory tract (classic respiratory viruses, including influenza, respiratory syncytial virus [RSV], human metapneumovirus [hMPV], parainfluenza virus [PIV], rhinovirus, and adenovirus) and viruses that can affect the respiratory tract opportunistically (ie, herpes simplex [HSV], cytomegalovirus [CMV] , and measles). The focus of this article is antivirals directed at classic respiratory viruses; excellent reviews of agents for the treatment of HSV and CMV infections can be found elsewhere. [1] [2] [3] However, there is significant effort being invested in novel antivirals for respiratory viruses often directed at novel targets, combinations designed to increase potency and reduce resistance emergence, therapeutic antibodies, and immunomodulatory agents selected to mitigate immunopathologic host responses; agents in advanced clinical development are reviewed briefly here, whereas more detailed reviews may be found elsewhere. [4] [5] [6] Few antiviral drugs are currently approved for treating respiratory virus infections and most of these are specific inhibitors of influenza viruses. The emergence of new pathogens like Middle East respiratory syndrome coronavirus has also led to screening efforts to identify new therapeutics. 7, 8 
M2 Inhibitors
The M2 ion channel allows hydrogen ions to flow into the viral particle and results in release of the RNA segments into the infected cell. Amantadine (Symmetrel) and rimantadine (Flumadine) are symmetric tricyclic amines that specifically inhibit the replication of influenza A viruses at low concentrations (<1.0 mg/mL) by blocking the action of this M2 protein. [9] [10] [11] When used against susceptible strains, both agents are 70% to 90% effective in preventing infection and reduce duration of fever and symptoms when used for treatment. [12] [13] [14] Although this class of drugs is specifically indicated for the prevention and treatment of influenza A infections, widespread resistance to all M2 inhibitors has been documented in circulating influenza A strains, and this class of agents is not currently recommended for the prevention or treatment of influenza. 15 Cross-resistance to both agents occurs as the result of single amino acid substitutions in the transmembrane portion of the M2 protein. 11 The resistant virus seems to retain wild-type pathogenicity and causes an influenza illness indistinguishable from that caused by susceptible strains.
Both drugs achieve peak levels 3 to 5 hours after ingestion. [16] [17] [18] Amantadine and rimantadine come as 100-mg tablets and a syrup formulation (50 mg/ 5 mL). In adults, the usual dose for treatment or prevention of influenza A infection is 100 mg every 12 hours for both drugs. Amantadine is excreted unchanged by the kidney, whereas rimantadine undergoes extensive metabolism by the liver before being excreted by the kidney; as a result, dose adjustment with renal dysfunction is required. The most common side effects of the M2 inhibitors are minor central nervous system complaints (anxiety, difficulty concentrating, insomnia, dizziness, headache, and jitteriness) and gastrointestinal upset, which are particularly prominent in the elderly and those with renal failure. 17 Patients who receive amantadine may develop antimuscarinic effects, orthostatic hypotension, and congestive heart failure. Rates of adverse effects are lower for rimantadine than amantadine. 17, 19 Given drug-drug interactions, care should be used when coadministering either agent with antihistamines or anticholinergic drugs, trimethoprim-sulfamethoxazole, triamterene-hydrochlorothiazide, quinine, quinidine, monoamine oxidase inhibitors, antidepressants, and minor tranquilizers. 20 
Neuraminidase Inhibitors
Influenza A and B viruses possess a surface glycoprotein with neuraminidase activity that cleaves terminal sialic acid residues from various glycoconjugates and destroys the receptors recognized by viral hemagglutinin. This activity is essential for release of virus from infected cells, for prevention of viral aggregates, and for viral spread within the respiratory tract. 21 Oseltamivir (Tamiflu, a prodrug of the active carboxylate), laninamivir (Inavir), peramivir (Rapiacta, Peramiflu) and zanamivir (Relenza) are sialic acid analogues that potently and specifically inhibit influenza A and B neuraminidases by competitively and reversibly interacting with the active enzyme site. 22, 23 Oseltamivir and zanamivir are globally available, whereas laninamivir is approved in Japan and peramivir is approved in China, Japan, South Korea, and the United States.
Laninamivir
Laninamivir octanoate (CS-8958) is a prodrug that is converted in the airway to laninamivir (R-125489), the active neuraminidase inhibitor, and is retained at concentrations that exceed the IC 50 (50% inhibitory concentration) for most influenza neuraminidases for at least 240 hours (10 days) after a single inhalation of 40 mg. 24 Only 15% of the drug is systemically absorbed after inhalation. Dose adjustment is not indicated for renal or hepatic insufficiency. Laninamivir octanoate (CS-8958) is currently only approved in Japan for the treatment and prevention of influenza A and B infection and is available as a 20mg dry powder inhaler. A single inhalation of 20 mg daily for 2 days is recommended for prophylaxis, whereas a single inhalation of 40 mg for individuals greater than or equal to 10 years of age and 20 mg for children less than 10 years of age are recommended for treatment.
Laninamivir was associated with more rapid time to alleviation of influenza illness caused by infections by seasonal H1N1 virus with the H275Y substitution in children compared with a standard 5-day oseltamivir regimen, whereas studies in adults showed noninferiority versus oseltamivir in such patients. 25, 26 Laninamivir shows a similar duration of fever in ambulatory children compared with patients treated with zanamivir. 27, 28 Among household contacts of an index patient with influenza, 2 and 3 days of laninamivir 20 mg daily was associated with a 77% and 78% protective efficacy, respectively, compared with placebo. 29 Common side effects include nausea, vomiting, diarrhea, and dizziness. 25, 26 Laninamivir was not associated with significant bronchospasm or other respiratory adverse effects in patients with chronic respiratory disease. 30 Oseltamivir Oral oseltamivir ethyl ester is well absorbed and rapidly cleaved by esterases in the gastrointestinal tract, liver, or blood. The bioavailability of the active metabolite, oseltamivir carboxylate, is estimated to be w80% in previously healthy persons. 31 The plasma elimination half-life is 6 to 10 hours but is more prolonged in the elderly, although dose adjustments are not generally necessary. Administration with food seems to decrease the risk of gastrointestinal upset without decreasing bioavailability. Both the prodrug and parent are eliminated primarily unchanged through the kidney by glomerular filtration and anionic tubular secretion. The dose should be reduced by half for patients with a creatinine clearance less than 30 mL/min, and further reductions when clearance is less than 10 mL/min. 32 Distribution is not well characterized in humans, but peak bronchoalveolar lavage, middle ear fluid, and sinus fluid levels are similar to plasma levels. 31 Oseltamivir is indicated for the prevention of influenza A and B in patients greater than or equal to 1 year old, with dosing once a day, and for the treatment of patients greater than or equal to 2 weeks of age who have influenza A and B, with twice-a-day dosing. Oseltamivir is available for oral delivery only. Oseltamivir comes as 30-mg, 45-mg, and 75-mg tablets and as a white tutti-frutti-flavored suspension (360-mg oseltamivir base for a final concentration of 6 mg/mL). The approved adult dose for treatment is 75 mg twice daily for 5 days and for prophylaxis is 75 mg once daily. Pediatric dosing is based on weight and is outlined in Table 1 . Efficacy of prophylaxis is 84% to 92% in protecting unvaccinated patients when given for 10 days to 8 weeks. 31, 33 Caution should be used with prescribing oseltamivir for prophylaxis in patients exposed to an index case because prophylaxis has been associated with emergence of resistant mutants 34 ; empiric therapy or monitoring is generally recommended in these cases as a result.
Among ambulatory adults with uncomplicated influenza A or B, oseltamivir 75 mg twice daily for 5 days when started within the first 2 days of symptoms was associated with a shorter time to alleviation of uncomplicated influenza illness (29-35 hours shorter) and with reductions in severity of illness, duration of fever, time to return to normal activity, quantity of viral shedding, duration of impaired activity, and complications leading to antibiotic use, particularly bronchitis, compared with placebo in previously healthy adults. 13, 15, 35 Pediatric studies enrolling children as young as 2 weeks of age showed that oseltamivir is safe and is associated with significantly reduced illness duration and severity, time to resumption of full activities, and the occurrence of complications leading to antibiotic use (particularly acute otitis media). [36] [37] [38] [39] [40] Most existing literature on the safety and efficacy of oseltamivir in hospitalized adults and children suggests that, among such high-risk and hospitalized individuals, there is a benefit to starting antiviral therapy through at least 5 days after symptom onset, with the greatest benefit in patients started within 48 hours after symptom onset. [41] [42] [43] [44] [45] [46] All of the studies in hospitalized adults suggest that early therapy is associated with reduced incidence of lower respiratory tract complications, requirement for intensive care unit (ICU)-level care, duration of illness, duration of shedding, and mortality. 13, 15, 43, 44, 46 Duration of therapy has not been well studied but data suggest that longer duration of therapy (!10 days) may be required, particularly in critically ill patients and those with pneumonia. Viral replication in the lower airway does not correlate with quantity or duration of replication in the upper airway. Doubling the treatment dose of oseltamivir in hospitalized patients with influenza does not seem to increase virologic efficacy, except perhaps for influenza B infections, or clinical effectiveness, although one ICU-based randomized controlled trial reported that tripling the standard dose was associated with acceleration of viral RNA clearance from the respiratory tract. [47] [48] [49] Doses of oseltamivir should be given after hemodialysis; dosing must be adjusted for renal insufficiency and renal replacement therapy (see Table 1 ). There are conflicting data about optimal dosing of oseltamivir in pregnant women, with some studies suggesting a need for higher doses (75 mg 3 times a day), whereas others suggest that no dose adjustment is needed. [50] [51] [52] Current guidelines recommend treating pregnant women with influenza infection with one of the approved neuraminidase inhibitors. The recommended pediatric dosage is listed in Table 1 .
Oral oseltamivir is generally well tolerated and no serious end-organ toxicity has been found in controlled clinical trials. Oseltamivir is associated with nausea; abdominal discomfort; and, less often, emesis in a minority of treated patients, but this can be ameliorated by giving food with each dose. Other infrequent possible adverse events include insomnia, vertigo, and fever. Postmarketing reports suggest that oseltamivir may be associated, rarely, with skin rash, hepatic dysfunction, or thrombocytopenia. In addition, there have been reports of abnormal neurologic and behavioral symptoms that have, rarely, resulted in deaths, mostly among children; most of these reports have come from Japan. Existing data suggest that these events are more likely secondary to influenza infections than oseltamivir therapy. 53, 54 It is currently recommended that patients be monitored closely for behavioral abnormalities.
No clinically significant drug interactions have been recognized to date, including studies with amoxicillin, aspirin, and acetaminophen. No interactions with the cytochrome P450 enzymes occur in vitro and oseltamivir does not affect the steady-state pharmacokinetics of commonly used immunosuppressive agents. 55 However, probenecid blocks tubular secretion and doubles the half-life of oseltamivir. Protein binding is less than 10%.
Peramivir
Peramivir has low oral bioavailability and is therefore delivered intravenously. Peramivir achieves exceptionally high maximum concentrations (w45,000 ng/mL after 600-mg intravenous dose) with excellent concentrations of drug in the nasal and pharyngeal secrections. 56 Peramivir is predominately eliminated unchanged by renal excretion with a plasma terminal elimination half-life of 12 to 25 hours. 39, 57 Outside the United States, peramivir is available in 150-mg and 300-mg solutions for intravenous use, whereas peramivir is available in 200-mg solutions for intravenous use in the United States. Peramivir is approved as a single-dose infusion for the treatment of previously healthy adults with uncomplicated influenza in the United States; nonetheless, it has been studied for treatment of complicated influenza in hospitalized adults and is the only intravenous therapy currently approved for the treatment of influenza. Placebo-controlled studies of a single 300-mg to 600-mg infusion of peramivir was associated with a significantly shorter time to alleviation of symptoms, significantly shorter time to resumption of patients' usual activities, and more rapid clearance of virus. 58 A single 300-mg to 600-mg infusion of peramivir was also noninferior to 5 days of oral oseltamivir 75 mg twice a day in a season when many of the viruses were resistant to oseltamivir as the result of the H275Y mutation; these data challenge the efficacy of peramivir in the management of viruses with the H275Y mutation. 59 Peramivir has also been investigated in several studies in hospitalized adults and children but is not specifically approved for this indication. In all studies, multiple doses of peramivir were used and findings suggest that single-dose therapy is not appropriate for severely ill patients. The first study, conducted in Japan, randomized 37 high-risk patients (those with diabetes or chronic respiratory tract diseases or patients being treated with drugs that suppress immune function) to receive 300 mg or 600 mg of peramivir daily with the duration of treatment (1-5 days) based on clinical improvement, defined as resolution of fever or judgment by the principal investigator or subinvestigator that continued administration was unnecessary. 60 The median durations of influenza symptoms were 114.4 hours in the 300-mg group and 42.3 hours in the 600-mg group (hazard ratio [90% confidence interval], 0.497 [0.251-0.984]) with a similar trend in time to resolution of fever. All subsequent studies have been larger, randomized, multinational studies. In the phase 2 study, 5 days of 200 mg or 400 mg of peramivir every day was compared with oral oseltamivir 75 mg twice a day in hospitalized adults. There was a trend toward more rapid resumption of usual activities in peramivir-treated patients and greater reductions of influenza B viral titers in the nasopharynx than oseltamivir over the first 48 hours. 61 A phase 3 multidose regimen was an open-label, multinational, randomized study that was started during the 2009 A/H1N1 pandemic (October 2009 to October 2010), and was designed to compare the safety and tolerability of 2 dosing regimens of peramivir in hospitalized patients. 62 Two-hundred and thirty-four patients were randomized to receive 5 days of 300 mg of peramivir twice daily or 600 mg of peramivir once daily. The overall time to clinical resolution (TTCR) was 92 hours in the intent-to-treat infected (ITTI) group with a median time of 42 hours in the 300-mg group and 166 hours in the 600-mg group. The subjects on the 600-mg regimen ITTI analysis were noted to have higher need for supplemental oxygen at randomization, higher baseline APACHE score, and higher need for ICU admission before randomization than the subjects randomized to the 300-mg regimen, and multivariate analysis showed that the difference in TTCR between groups could be explained by differences in severity of illness before randomization. Virologic response, as measured by time-weighted change in virus titer from baseline to 48 hours, was À1.51 TCID 50 (Median Tissue Culture Infectious Dose)/mL without significant difference between the two doses (P 5 .65). In addition, no treatment differences were seen in the percentage of subjects who remained culture positive or reverse transcription polymerase chain reaction positive at 48, 72, and 96 hours postenrolment. The second phase III study was a double-blind, randomized trail conducted between September 2009 and November 2012 and enrolled 338 patients. 63 Patients were randomized to receive peramivir or standard of care in a 2:1 ratio. Only 121 patients had confirmed influenza and did not receive an NAI (neuraminidase inhibitor) as part of Standard of Care (SOC) (ITTI-non-NAI group) and were randomized to placebo (n 5 43) or peramivir (n 5 78) and 217 patients with confirmed influenza received NAI as part of SOC (ITTI-NAI group) and were randomized to placebo (n 5 73) or peramivir (n 5 144). Of note, there were important differences between the ITTI-non-NAI group and the ITTI-NAI group, namely lower mean body mass index (24.7 vs 29.1 kg/m 2 ) and lower influenza vaccination rate (5% vs 23%) in the ITTI-non-NAI group. In addition, the non-NAI SOC subjects had shorter symptom duration (32% vs 48% symptoms >48 hours), and were less likely to smoke (13% vs 23%), have abnormal chest radiographs at baseline (27% vs 45%), require supplemental oxygen (26% vs 36%), or have measurable virus titers at baseline (31% vs 50%). The study was terminated for futility after interim analysis. Peramivir-treated subjects in the non-NAI SOC population showed a modest, but not statically significant (P 5 .97), improvement in TTCR compared with subjects receiving SOC alone (42.5 vs 49.5 hours), with similar results observed in the NAI SOC population (peramivir vs placebo, 41.8 vs 48.9 hours; P 5 .74).
The largest pediatric study was a multicenter, open-labeled, uncontrolled study during the 2009 A/H1N1 pandemic. 64 One-hundred and six pediatric subjects, aged 125 days to 15 years, with confirmed A/H1N1 influenza received intravenous peramivir infusion at 10 mg/kg (500 mg maximum) once daily and clinical response, adverse events, and pharmacokinetics were assessed. Median time to resolution of fever was 20.6 hours, time to resolution of symptoms was 29.1 hours, and 92.9% had viral clearance by day 6 of treatment. Of note, TTCR in this pediatric study was shorter than the time noted in the adult trials. Taken together, these results suggest that intravenous peramivir likely has similar efficacy to oral oseltamivir and can be considered as an alternative to oral therapy in patients who cannot take oral therapy or in whom oral absorption is in question.
Because peramivir is renally cleared, dosing must be adjusted based on renal function (see Table 1 ). 65, 66 There are limited data to guide dosing of peramivir in children, particularly among neonates. 65 No dose adjustments are needed for hepatic impairment. Recognized adverse events associated with the administration of peramivir are diarrhea, nausea, vomiting, and decreased neutrophil count; other less common adverse events observed in studies to date include dizziness, headache, somnolence, nervousness, insomnia, feeling agitated, depression, nightmares, hyperglycemia, hyperbilirubinemia, increased blood pressure, cystitis, electrocardiogram abnormalities, anorexia, and proteinuria. 67 
Zanamivir
The oral bioavailability of zanamivir is low (<5%), and most clinical trials have used intranasal or dry powder inhalation delivery. Following inhalation of the dry powder, approximately 7% to 21% is deposited in the lower respiratory tract and the remainder in the oropharynx. 68, 69 Median zanamivir concentrations are more than 1000 ng/ mL in induced sputum 6 hours after inhalation and remain detectable up to 24 hours. The peak plasma concentration averages 46 mg/L after a single 16-mg inhalation of zanamivir. The proprietary inhaler device for delivering zanamivir is breath actuated and requires a cooperative patient. 70 Intravenous zanamivir displays linear dosing kinetics and the volume of distribution is approximately equivalent to that of extracellular water (16 L). 68 Intravenous zanamivir provides high peak plasma concentrations (w35,000 ng/mL after 600-mg dose in adults). 71 Ninety percent of the drug is excreted unchanged in the urine with an elimination half-life of approximately 2 hours. Intravenous zanamivir clearance is highly correlated with renal function. 72 Zanamivir is approved for the prevention and treatment of acute, uncomplicated influenza in ambulatory adults and children and is delivered by inhalation with a proprietary breath-activated device (Diskhaler). The usual adult treatment dose is 2 inhalations (10 mg) twice a day for 5 days and once a day for 10 days for prophylaxis. Intravenous zanamivir is currently only available by compassionate use.
Once-daily inhaled zanamivir for 10 days to 4 weeks is between 79% and 84% effective in preventing laboratory-confirmed symptomatic influenza. 69 Zanamivir is indicated for the treatment of uncomplicated acute illness caused by influenza A and B viruses in adults and pediatric patients 7 years of age and older who have been symptomatic for no more than 2 days. 15 Inhaled zanamivir in adults has consistently shown at least 1 less day of disabling influenza symptoms, and most studies have found a reduction in the number of nights of disturbed sleep, in time to resumption of normal activities, and in the use of symptom relief medications. 13, 15 Similar therapeutic benefits have also been shown in children aged 5 to 12 years. 73 Zanamivir has also been associated with a 40% reduction in lower respiratory tract complications of influenza leading to antibiotics, particularly bronchitis and pneumonia. 74 Zanamivir seems generally well tolerated and effective in treating influenza in patients with mild to moderate asthma or, less often, chronic obstructive pulmonary disease. 74, 75 Intravenous zanamivir is in advanced clinical development and has been used in seriously ill patients with influenza, especially those with suspected oseltamivir-resistant variants. Most of the emergency investigational new drug uses of intravenous zanamivir were in patients who were clinically failing other antiviral therapy, with at least 25% of patients having proven or clinically suspected resistance to oseltamivir; 10.5% of patients died. 76 A phase 2 study in critically ill patients with pandemic 2009 H1N1 found that treatment was associated with significant antiviral effects, even though therapy was initiated a median of 4.5 days after symptom onset. Of patients with influenza detected on initial sample, 2 days of therapy were associated with a median 1.42 log 10 copies per milliliter decline in viral load. 71 There were no drug-related trends in safety parameters identified. The 14-day and 28-day all-cause mortalities were 13% and 17%, respectively. 71 A phase 3 study comparing intravenous zanamivir and oral oseltamivir in hospitalized adults was recently completed but results are not available at the time of the writing.
Dose adjustment is not necessary for renal or hepatic dysfunction. Certain populations, particularly very young, frail, or cognitively impaired patients, may have difficulty using the drug delivery system. 70 Intravenous zanamivir requires dose adjustment for renal insufficiency. All patients should receive an initial 600-mg loading dose. The maintenance dose and dosing interval are reduced with worsening renal function and it should be dosed according to updated guidance provided with the compassionate use drug. 71, 72 Topically applied zanamivir is generally well tolerated in controlled studies, including those involving patients with asthma and chronic obstructive pulmonary disease. 75 Postmarketing reports indicate that bronchospasm may be an uncommon but potentially severe problem, particularly in patients with acute influenza and underlying reactive airway disease. 15 Anecdotal reports of hospitalization and fatality indicate that inhaled zanamivir should be used cautiously in such patients. 15 The currently available inhaled formulation cannot be used in patients on ventilators because obstruction of filters and death of patients has been reported. One randomized controlled trial in ambulatory adults found that the combination of inhaled zanamivir and oral oseltamivir was less effective than oseltamivir monotherapy. 77 Zanamivir is not associated with teratogenic effects in preclinical studies (US Food and Drug Administration pregnancy category C) and should be considered as an option in pregnant women with proven influenza. 15 Ribavirin Ribavirin (Virazole, Rebetol) is a guanosine analogue with a wide range of antiviral activity, including influenza viruses, RSV, and parainfluenza viruses. Ribavirin is rapidly phosphorylated by intracellular enzymes and the triphosphate inhibits influenza virus RNA polymerase activity and competitively inhibits the guanosine triphosphate-dependent 5 0 capping of influenza viral messenger RNA. In addition, ribavirin depletes cellular guanine pools 78, 79 and may inhibit virus replication by lethal mutagenesis. Oral ribavirin has a bioavailability of 33% to 45% in adults and children and achieves peak plasma concentration of 0.6 mg/mL 1 to 2 hours after ingestion of a 400-mg dose in adults. Ribavirin has a short initial (0.3-0.7 hour) and a long terminal (18-36 hours) phase half-life and is eliminated by hepatic metabolism and renal clearance. 80 After aerosol administration, plasma levels increase with exposure and range from 0.2 to 1 mg/mL. Respiratory secretions have levels up to 1000 mg/mL, which decline with a half-life of 1.4 to 2.5 hours.
Ribavirin is available in 3 formulations: oral (approved for combined use in hepatitis C), intravenous (investigational in the United States), and aerosol. Ribavirin for aerosolization is available as a solution of 6 g/100 mL, which is diluted to a final concentration of 20 mg/mL and delivered by small particle aerosol for 12 to 18 hours with a proprietary device (SPAG-2 nebulizer). A higher concentration of aerosol solution (60 mg/mL) has been given over 2 hours 3 times daily in some studies and seems well tolerated. 81 Ribavirin also comes in 200-mg tablets and sterile solution for injection.
Ribavirin aerosol is currently indicated for the treatment of severe RSV in children. Trials of aerosolized ribavirin for the treatment of severe RSV infection in infants have shown no consistent effect on duration of hospitalization time, mortality, or pulmonary functions. 13 Current guidelines recommend that aerosolized ribavirin be considered in the treatment of high-risk infants and young children, as defined by congenital heart disease, chronic lung disease, immunodeficiency states, prematurity, and age less than 6 weeks, as well as for those hospitalized with severe illness. 13 Aerosolized ribavirin has shown minimal efficacy in treating influenza in hospitalized children. 82 Ribavirin has also been studied for the treatment of RSV and parainfluenza virus infections in immunocompromised patients. Intravenous ribavirin seems to be ineffective in reducing RSVassociated mortality in hematopoietic stem cell transplant (HSCT) patients with RSV pneumonia; there may be benefit among lung transplant recipients. 83 Aerosolized ribavirin may provide benefit in selected patient groups with less severe RSV disease. Survival was improved when treatment was started before respiratory failure or when infection was limited to the upper respiratory tract. 84 Observational studies suggest that combination therapy with antibodies (either intravenous immunoglobulin, RespiGam, or palivizumab) seems more effective, particularly when started before severe respiratory distress. 84 Oral ribavirin has been tried in the management of RSV with variable success. 85 In the management of parainfluenza virus in bone marrow transplant recipients, 2 case series found that aerosolized ribavirin failed to improve 30-day mortality or reduce the duration of viral replication relative to no treatment. 86 Ribavirin has not been clearly shown to have consistent clinical activity for the treatment of adenovirus infections and is not recommended for this indication. 87 Systemic ribavirin is contraindicated in patients with creatinine clearance less than 50 mL/min and the dose should be reduced by one-third for patients less than 10 years of age. Dose adjustment is needed if there is a substantial decline in hematocrit and the drug should be discontinued if the hemoglobin level decreases to less than 8.5 g/dL. Systemic ribavirin can cause a doserelated extravascular hemolytic anemia and, at higher doses, suppression of bone marrow release of erythroid elements. Aerosolized ribavirin can cause bronchospasm, mild conjunctival irritation, rash, psychological distress if administered in an oxygen tent, and (rarely) acute water intoxication. Bolus intravenous administration may cause rigors. Antagonism of both drugs may occur when ribavirin is combined with zidovudine. Ribavirin is contraindicated in pregnant women and in male partners of women who are pregnant because of teratogenicity of the drug. Pregnancy should be avoided during therapy and for 6 months after completion of therapy in both female patients and in female partners of male patients taking ribavirin (pregnancy category X).
Nitazoxanide
Nitazoxanide is an antiparasitic agent with apparent antiviral activities, including influenza virus and norovirus. 88, 89 The mechanism of action of nitazoxanide against influenza viruses is through blockage of maturation of the viral hemagglutinin at the posttranslational stage. 89 Nitazoxanide reduced symptom duration in phase 2b/3 trials in adults and adolescents with uncomplicated influenza 90 ; a phase 3 trial is underway. 91 The drug also showed clinical efficacy in a small randomized trial of viral gastroenteritis. 92, 93 Cidofovir No antiviral agents are specifically approved for the treatment of adenovirus. Cidofovir, which is a potent inhibitor of adenovirus in cell culture, has been used (either 5 mg/kg weekly for 2 weeks then every other week or 1 mg/kg 3 times a week), but data suggest that its efficacy/toxicity (predominantly nephrotoxicity) ratio is narrow. As a result, its use is limited generally to patients with significant evidence of disseminated adenovirus disease, preemptive treatment in pediatric HSCT patients with persistent replication. Earlier onset of therapy generally is associated with the best results and failure to develop a significant (1 log or greater) reduction in adenovirus load within 2 weeks of initiation of therapy is generally associated with poor outcomes. 87, 94 Combination Therapy Combination therapy has been studied using a variety of combinations of antivirals and adjunctive therapies with the hope of improving antiviral activity, improving clinical outcomes, and reducing the risk of development of antiviral resistance for influenza. 95 There is evidence of in vitro synergy or additive effects with oseltamivir and amantadine; oseltamivir and favipiravir; peramivir and rimantadine; peramivir and oseltamivir; and a triple combination of amantadine, ribavirin, and oseltamivir. [95] [96] [97] [98] [99] In a study of oral rimantadine and nebulized zanamivir in an era with virus susceptible to M2 inhibitors, the combination was associated with trends toward faster cough resolution and lesser risk of adamantane resistance emergence. 100 The combination of oseltamivir and either convalescent plasma or hyperimmune globulin is associated with reduced mortality compared with patients treated with oseltamivir alone. 95, 101 A study of oseltamivir, sirolimus, and corticosteroids was likewise associated with reduced mortality among critically ill patients. 102 The triple combination of amantadine, ribavirin, and oseltamivir was found to have similar PKs (pharmacokinetics) to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients; additional clinical studies of this triple combination are currently underway (NCT01227967). Likewise, the combination of oseltamivir and nitazoxanide has been studied; at the time of writing, the study is complete but results have not been made public (NCT01610245). Despite their theoretic benefits, the optimal use of combination therapy is still under investigation. 95 Similarly, combinations of therapy, typically ribavirin plus antibody preparations, have also been studied for the treatment of RSV and parainfluenza virus in immunocompromised patients. For RSV, the lowest rate of progression to lower tract disease and lowest mortality has been observed with the combination of aerosolized ribavirin and an antibody preparation (either RSV immunoglobulin, intravenous immunoglobulin, or palivizumab). 84 
Investigational Agents
Favipiravir (T-705) Favipiravir is a broad antiviral that seems to inhibit RNA-dependent RNA polymerase but not mammalian RNA or DNA synthesis. It is approved in Japan for treatment of influenza in selected circumstances and phase 3 studies from ex-Japan for the treatment of acute uncomplicated influenza have recently been completed but results are pending. 103 The antiviral has in vitro activity against several RNA viruses, including West Nile virus, dengue virus, yellow fever virus, and Ebola.
FluDase (DAS181)
DAS181 is a recombinant fusion protein that cleaves sialic acid residues from respiratory epithelial cell surfaces, and prevents influenza and parainfluenza viral infection. [104] [105] [106] [107] A phase 2 trial showed reduction in influenza viral load in healthy adults but had a more limited impact on symptoms. 108 DAS181 has also been used to treat several immunocompromised patients with PIV infection with a complete or partial response shown in 81% of patients. [109] [110] [111] [112] [113] A phase 2 randomized trial of DAS181 in immunocompromised hosts with PIV lower respiratory tract infection is ongoing.
Presatovir (GS-5806) GS-5806 is an oral RSV entry inhibitor that showed reductions in viral load and clinical severity in phase 1 studies. [114] [115] [116] Phase 2 trials are underway in hospitalized patients and adult HSCT and lung transplant recipients. [117] [118] [119] [120] ALS-8176 ALS-8176, a nucleoside analogue targeting RSV polymerase, showed reduction of viral load and decreased disease severity in a human challenge model. 121 Studies in hospitalized infants are ongoing. 122 
ALN-RSV01
ALN-RSV01, a small interfering RNA, was effective in a challenge model 123 and reduced cumulative daily symptom scores and incidence of progressive bronchiolitis obliterans syndrome in lung transplant recipients. 124, 125 There is currently no ongoing clinical development.
